Matrix GLA Protein Modulates Differentiation Induced by Bone Morphogenetic Protein-2 in C3H10T1/2 Cells*

Kristina BoströmDagger, David Tsao, Sam Shen, Ying Wang, and Linda L. Demer

From the Division of Cardiology, Departments of Medicine and Physiology, UCLA School of Medicine, Los Angeles, California 90095-1679

Received for publication, September 5, 2000, and in revised form, January 8, 2001




    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Matrix GLA protein (MGP) is ubiquitously expressed with high accumulation in bone and cartilage, where it was found to associate with bone morphogenetic proteins (BMP) during protein purification. To test whether MGP affects BMP-induced differentiation, three sets of experiments were performed. First, pluripotent C3H10T1/2 cells transfected with human MPG (hMGP) or antisense to hMGP (AS-hMGP) were treated with BMP-2. In cells overexpressing hMGP, osteogenic and chondrogenic differentiation was inhibited indicating decreased BMP-2 activity. Conversely, in cells overexpressing AS-hMGP, BMP-2 activity was enhanced. Second, cells were prepared from homozygous and heterozygous MPG-deficient mice aortas. When treated with BMP-2, these cells underwent chondrogenic and osteogenic differentiation, respectively, whereas controls did not. Third, FLAG-tagged hMGP with the same biological effect as native hMGP inhibited BMP-induced differentiation, when exogenously added to culture media. Together, these results suggest that MGP modulates BMP activity. To test whether hMGP fragments would retain the effect of full-length hMGP, three subdomains were overexpressed in C3H10T1/2 cells. In cells expressing the mid-region, alone (amino acids (aa) 35-54) or in combination with the N terminus (aa 1-54) but not the C terminus (aa 35-84), osteogenic differentiation was enhanced and occurred even without added BMP-2. Thus, two subdomains had the opposite effect of full-length hMGP, possibly due to different expression levels or domain characteristics.




    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Matrix GLA protein (MGP)1 is a small ubiquitous matrix protein containing carboxyglutamic acid (GLA) (calculated mass of mature protein 10.4 kDa), initially isolated from bone and characterized by Price et al. (1). Results from other investigators suggest that MGP affects differentiation in developing cartilage and bone. Luo et al. (2) observed that MGP is expressed in early and late stages of chondrogenic differentiation but not in the intermediate stage. Yagami et al. (3) found that MGP had an effect on mineralization in chondrocytes that was dependent on cell stage; it affected mineralization in hypertrophic chondrocytes but not in proliferative chondrocytes. They also found that overexpression of MGP in developing limb buds delayed chondrocyte maturation and blocked endochondral ossification. In MGP null (MGP-/-) mice (4), the epiphyseal growth plates of bones showed inappropriate calcification in the layer of proliferating chondrocytes that failed to differentiate into hypertrophic chondrocytes. In addition, the mice unexpectedly developed severe vascular calcification, resulting from a replacement of the aortic medial layer by chondrocyte-like cells, producing a typical cartilage matrix that progressively calcified.

When Urist and colleagues (5) first discovered bone morphogenetic protein (BMP), they observed a tight association with MGP in vitro during protein purification requiring strong denaturants to break. Although complex formation was not shown in vivo or in situ, it was suggested that MGP may sequester BMP in bone tissue and as such regulate its activity (5). Since BMP mediates its biological response through a cell surface receptor, MGP could potentially act extracellularly to form an inactive complex with BMP. It has not been shown whether MPG affects BMP function by forming such a biologically inactive complex whose formation blocks BMP action on cells. In this paper, we test the hypothesis that the mechanism for the effect of MGP on cell differentiation is through modulation of BMP activity.

A useful model for assaying BMP-2 functional activity in mesenchymal differentiation is the "undifferentiated" mesenchymal cell line, C3H10T1/2. These multipotent mouse embryonic cells, also known as vascular precursor cells (6), differentiate along adipogenic, osteogenic, and chondrogenic lineages when stimulated with BMP-2 (7, 8). Once stimulated, colonies of lineage form within the same culture and time frame.

To test the hypothesis that MGP modulates BMP-2-induced mesenchymal differentiation, we overexpressed human MGP (hMGP) and antisense to hMGP (AS-hMGP), and we assayed differentiation along each lineage in response to recombinant human BMP-2 (rhBMP-2). We also compared responses to rhBMP-2 in cells isolated from aortas of homozygous and heterozygous MGP-deficient mice to those isolated from aortas of wild-type mice. FLAG-tagged hMGP with the same biological effect as native hMGP was used to localize the MGP effect to the extracellular space. In addition, the effect of overexpression of selected hMGP subdomains was compared with that of full-length hMGP.

These results support the concept that MGP modulates BMP activity in mesenchymal differentiation and that the physical interaction observed during protein purification from bone may have physiological significance.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Vector Construction-- Full-length human MGP (hMGP) cDNA subcloned into the EcoRI site of the pBSSK(-) plasmid (Stratagene, La Jolla, CA) was obtained from the American Tissue Culture Collection (Manassas, VA) (9). The hMGP sequence was excised and subcloned into pcDNA3.1(+) Zeo (Invitrogen, Carlsbad, CA) in sense or antisense orientation using the HindIII and XbaI sites for sense orientation, and the NotI and ApaI sites for antisense orientation. A schematic overview of the vectors used in this study is provided in Fig. 1.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic overview of human MGP vectors. The full-length hMGP and selected subdomains were inserted into the pcDNA3.1(+) plasmid as described under "Materials and Methods." N, N terminus; C, C terminus; P, phosphorylation site; C-C, cystine bridge; gamma , gamma -carboxylation site.

To construct the N-MGP vector (containing the N-terminal and the central region of hMGP, aa 1-54, Fig. 1), the correct fragment was generated by PCR of hMGP cDNA using primers ERIFL-5' and MGPX-3' (Table I) and then subcloned into the EcoRI and XbaI sites in the pcDNA3.1(+) plasmid after digestion of the restriction enzyme sites in the primers. To construct the mid-MGP vector (containing the central region of hMGP alone, aa 35-54, Fig. 1), the C-MGP vector (containing the C-terminal and the central region of hMGP, aa 35-84, Fig. 1), and the control vector (containing only the leader sequence, Fig. 1), the hMGP-leader sequence was first excised from the hMGP cDNA using EcoRI and a HinfI site located just downstream of the leader sequence. Fragments containing the C-MGP and the mid-MGP regions were generated by PCR of hMGP cDNA using primers MGPH-5' and XBAFL-3', and MGPH-5' and MGPX-3' (Table I) respectively. The fragments were subsequently ligated into the pcDNA3.1(+) vector downstream of and in frame with the leader sequence, after digestion of the restriction enzyme sites in the PCR primers. For the control vector, the EcoRI-HinfI fragment was ligated into pcDNA3.1(+) digested with EcoRI and EcoRV. This vector contains the leader sequence alone followed by a stop codon 1 base downstream of the HinfI site.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Primer sequences for vector construction and RT-PCR

To construct the FLAG-tagged hMGP vector, a fragment containing full-length hMGP in which the stop codon had been replaced by an XhoI site, was generated by PCR of hMGP cDNA using primers ERIFL-5' and mgpFLAG-3' (Table I). The FLAG tag was placed in the C terminus of the resulting protein by subcloning the fragment into the EcoRI and XhoI sites in the pCMV-Tag4 plasmid (Stratagene), after digestion of the restriction enzyme sites in the primers.

To construct the human BMP-2 vector, the correct fragment containing the complete coding sequence was generated by PCR of human BMP-2 cDNA using primers bmp2ERI-5' and bmp2XBA-3' (Table I), and then subcloned into the EcoRI and XbaI sites in the pcDNA3.1(+) plasmid, after digestion of the restriction enzyme sites in the primers.

All constructs were confirmed by restriction enzyme analysis and DNA sequencing of the complete coding sequences.

Cell Culture-- C3H10T1/2 mouse cells were cultured in alpha -minimum Eagle's medium with Earle's salt (Irvine Scientific, Santa Ana, CA) and HEK293 cells in Dulbecco's modified Eagle's medium (Irvine Scientific), both supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone Laboratories, Logan, UT), penicillin (100 units/ml), streptomycin (100 units/ml), sodium pyruvate (1 mmol/L), and L-glutamine (2 mM).

To prepare aortic cells from MGP-deficient and control mice, whole aortas were obtained and cleaned of visible surrounding fat and other tissue. Aortic cells from heterozygous MGP+/- and normal mice were prepared by enzymatic digestions with cold trypsin as described previously (10). Because of cartilaginous metaplasia, homozygous MGP-/- aortas required use of enzymatic digestion adapted to cartilage as described previously (10) for release of cells. After digestion, the cells were plated in gelatin-coated 12-well plates and grown in F-12 medium (Irvine Scientific) supplemented with 20% heat-inactivated FBS, penicillin (100 units/ml), streptomycin (100 units/ml), sodium pyruvate (1 mmol/liter), and L-glutamine (2 mM). The MGP-/- cells did not tolerate subsequent trypsinization and re-plating and thus were treated with rhBMP-2 as they reached ~75% confluency. Cells from normal mice and MGP+/- mice were trypsinized, plated, and treated with rhBMP-2 as they reached ~75% confluency. Treatment with rhBMP-2 was continued for a total of 14-16 days. The cells were then taken to histochemical staining, RT-PCR, or immunoblotting.

Transfections were performed using SuperfectTM (Qiagen, Chatsworth, CA), after optimization of the ratio of DNA to transfection agent as per manufacturer's instructions. Stable, mixed mass transfectants of C3H10T1/2 cells were selected and maintained by adding ZeocinTM (Invitrogen) at a concentration of 500 ng/ml to all culture media.

Recombinant human BMP-2 was graciously supplied by Genetics Institute or generated in our laboratory from HEK293 cells transiently transfected with the human BMP-2 vector. The concentration of rhBMP-2 in undiluted conditioned media was estimated by comparison with purified rhBMP-2 from Genetics Institute using Western blotting.

Differentiation Assay, C3H10T1/2 Cells-- Two thousand C3H10T1/2 cells were plated in 60-mm Petri dishes, or 150 cells were plated per well in 12-well plates. BMP-2 was added to the cultures the day after plating at a concentration of 500 ng/ml. Because of the sparse plating, the initial medium with rhBMP-2 was left on the cells for 7 days; thereafter, the medium was changed every 3-4 days for a total of 21 days. Cells in 60-mm Petri dishes were used for RT-PCR, immunoblotting, or immunoradiometric assay; cells in 12-well plates were used for histochemical staining.

RT-PCR-- Total RNA was isolated from cultured cells using an RNA isolation kit (Stratagene). Reverse transcription of 3 µg of total RNA was carried out for 90 min at 37 °C in 50 µl of RT buffer (as supplied by Stratagene), supplemented with 0.5 mM of each dNTP (Amersham Pharmacia Biotech), 50-80 units of RNase Block, 50 units of Moloney murine leukemia virus reverse transcriptase (both Stratagene), and 750 ng of oligo(dT) (10) (Roche Molecular Biochemicals) for priming.

PCR using primers to unique sequences in each cDNA was carried out in a volume of 10 µl, using Pfu buffer, 7 units of native Pfu polymerase (Stratagene), 0.1 µl of [alpha -32P]dCTP (Amersham Pharmacia Biotech), 25 ng of each primer, and 1 µl of template (from a 50-µl RT reaction). Thermal cycling was performed as follows: 1) initial denaturation at 96 °C for 2 min; 2) cycling for cDNA-specific number of cycles (Table I) between 96 °C for 1 min, cDNA-specific annealing temperature (Table I) for 2 min, and 72 °C for 2 min; and 3) final extension at 72 °C for 5 min.

For semi-quantitative PCR, the number of cycles was chosen so that amplification remained well within the linear range, as assessed by densitometry (NIH Image J, version 1.08i, public domain program) of standard curves for representative samples. An equal volume from each PCR was analyzed by 6% nondenaturing polyacrylamide gel electrophoresis, and dried gels were examined by autoradiography. For PCR generating DNA fragments for vector construction, the number of cycles was chosen to ensure sufficient amounts of generated product, usually 45 cycles.

Alkaline Phosphatase (AP) Assay-- Cells were plated in triplicate in 96-well plates at 100 cells per well. Sixteen hours later, 200 µl of conditioned media containing rhBMP-2 (estimated 600 ng/ml) alone or in combination with ~3-fold molar excess hMGP-FLAG was applied to the cultures. The initial medium was left on the cells for 6 days; thereafter, the medium was changed every 3-4 days for a total of 13-14 days.

Conditioned media containing either BMP-2 or hMGP-FLAG alone were prepared from HEK293 cells transfected with 16 µg of the respective plasmid per 100-mm culture dish. Conditioned media containing both BMP-2 and hMGP-FLAG were prepared from HEK293 cells transfected with 4 and 12 µg of the BMP-2 and the hMGP-FLAG plasmid, respectively, per 100-mm culture dish. In all cases, 5 ml of conditioned medium was collected after 48 h of incubation starting after transfection. Control media were collected form HEK293 cells transfected with empty vector.

To determine AP activity, the cells were washed once with phosphate-buffered saline and lysed by freeze-thawing twice in 50 µl of 0.2% Nonidet P-40 with 1 mM MgCl2. Cell lysates were assayed for AP activity by adding 150 µl of AP buffer (40 mg of Sigma 104 phosphate substrate dissolved in 20 ml of Sigma 221 Alkaline Buffer Solution diluted 1:2 with distilled water) per well and incubating for 60 min at 37 °C. Absorbance at 405 nm was read using a microplate reader (Molecular Devices, Sunnyvale, CA), and activity was expressed as units per mg of cellular protein.

Histochemical Staining-- Oil Red O, von Kossa, Alizarin Red, and Alcian Blue histochemical stains were performed using standard methods. Alkaline phosphatase stain was performed as described previously (11).

Immunoblotting-- For immunoblotting, 30 µg per sample of whole cell extract protein was electrophoresed through 3-8% NuPAGETM Tris acetate gels (NOVEX, San Diego, CA) or 4-12% NuPAGETM Bis-Tris (MOPS) gels for collagen IX and peroxisome proliferator-activated receptor gamma  (PPAR-gamma ), respectively. For detection of FLAG-tagged hMGP and BMP-2 in conditioned media, 30 µl of media were electrophoresed through 10% NuPAGETM Bis-Tris (MES) gels. Proteins were transferred to nitrocellulose filter using NuPAGETM Transfer buffer (NOVEX). The blots were incubated with specific antibodies to either collagen IX (monoclonal antibody MAB3304 (12), Chemicon International, Temecula, CA) at a concentration of 2.5 µg/ml, PPAR-gamma protein (polyclonal antibody H-100, Santa Cruz Biotechnology, Santa Cruz, CA) at a concentration of 1 µg/ml, the FLAG tag (polyclonal antibody F7425, Sigma) at a concentration of 1 µg/ml, or BMP-2 (polyclonal antibody H-51, Santa Cruz Biotechnology) at a concentration of 1 µg/ml. Specific antibody binding was visualized with the appropriate horseradish peroxidase-conjugated anti-IgG secondary antibody (Santa Cruz Biotechnology).

Immunoradiometric Assay-- Mouse osteocalcin was quantitated in undiluted conditioned culture medium after 4 days of incubation according to manufacturer's instructions using an immunoradiometric assay (Immutopics, San Clemente, CA), and the results were expressed as ng/ml. There was no cross-reactivity with bovine osteocalcin derived from FBS.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Transfection of Sense and Antisense Human MGP in C3H10T1/2 Mesenchymal Cells-- To determine the effect of MGP on BMP-2-directed differentiation, we used low density cultures of the multipotent mouse mesenchymal cell line, C3H10T1/2 cells, which commit to various mesenchymal lineages when stimulated with exogenous BMP-2 (7, 8), even after brief, transient exposures (7). Without stimulation, there are low levels of spontaneous differentiation at base line (7). We used these cells as a bioassay to study effects of MGP on BMP-2 response by varying MGP expression.

MGP expression is highly dependent on cell density in cultured rat kidney (NRK) cells (13); the expression at low density was barely detectable but increased significantly with culture density. We observed the same phenomenon in C3H10T1/2 cells, with barely detectable MGP expression 1 day after low density plating, increasing at least 12-13-fold after 3 weeks in culture.

To test the hypothesis that MGP affects cell differentiation through altered responses to BMP-2, we modulated the MGP expression at low cell density (i.e. minimal expression of endogenous MGP) conditions, using stable cell lines overexpressing human MGP (hMGP) or antisense to MGP (AS-hMGP). We used the human MGP sequence that can be distinguished from mouse MGP using RT-PCR.

One day after low density plating, cells transfected with hMGP had an estimated 3-fold increase in MGP signal (including both sense mouse and sense human MGP, Fig. 2). Also at low density, cells transfected with AS-hMGP had an estimated 3-fold increase in MGP signal (including both sense mouse and antisense human MGP, Fig. 2) compared with nontransfected control cells. Addition of BMP-2 in all experiments was performed at this low density state.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Relative expression at low density of hMGP (sense) and AS-hMGP (antisense) in C3H10T1/2 cells transfected with hMGP or AS-hMGP, respectively, compared with expression of mouse MGP in nontransfected (NT) control cells. The relative expression was determined by multiple cycles of RT-PCR using primers recognizing either both mouse and human MGP or human MGP alone. Multiple radiographs were scanned, and the values were normalized to GAPDH and expressed relative to the MGP expression of subconfluent NT control cells (1-fold). The results are shown as the mean and S.D. of at least three independent determinations.

Effect of MGP Overexpression on BMP-induced Differentiation-- To assess whether altered levels of MGP expression modulate BMP-2-induced differentiation, we established a differentiation assay in C3H10T1/2 cells following the methods of Wang et al. (7). Treatment with rhBMP-2 or control vehicle was started at low density and continued for 21 days to allow distinct colonies of differentiated cells to form. We used rhBMP-2 at a concentration of 500 ng/ml based on preliminary experiments showing that this concentration induced differentiation in nontransfected C3H10T1/2 cells detectable by both specific cell markers and histochemical stains used to identify osteogenic, chondrogenic, and adipogenic cell differentiation. RT-PCRs for osteocalcin (14) in combination with von Kossa and Alizarin Red stains were used to identify osteogenic differentiation, RT-PCR for collagen IX (15), and Alcian Blue stain to identify chondrogenic differentiation, RT-PCR for PPAR-gamma (16), and Oil Red O stain to identify adipogenic differentiation.

The response to BMP-2 differed with the transfected construct. Nontransfected cells at low density underwent differentiation into a mix of all three cell lineages with cells of each lineage grouped in colonies as expected. No difference was seen between nontransfected cells and control cells transfected with plasmid containing only the MGP-leader sequence. However, in cultures of cells overexpressing hMGP, BMP-2-induced differentiation was inhibited. Conversely, in cultures overexpressing AS-hMGP, osteogenesis and chondrogenesis were enhanced.

These effects were first evident in phenotypic changes. Cells overexpressing hMGP maintained a noninduced phenotype despite BMP-2 treatment (Fig. 3, middle panels). In contrast, even without BMP-2 treatment, AS-hMGP-expressing cells spontaneously underwent these phenotypic changes (Fig. 3, bottom panels).



View larger version (140K):
[in this window]
[in a new window]
 
Fig. 3.   Morphology of C3H10T1/2 cells transfected with hMPG and AS-hMGP after 14 days in culture with treatment with vehicle alone (left panels) or rhBMP-2 (500 ng/ml) (right panels). Nontransfected (NT) control cells are shown for comparison. Original magnification × 40.

In hMGP-overexpressing cells, cell-specific markers, osteocalcin and collagen IX, were inhibited based on semi-quantitative RT-PCR (Fig. 4). In fact, both osteocalcin and collagen IX expression showed a decreasing trend in BMP-2-treated cells. In contrast, in AS-hMGP-overexpressing cells, osteocalcin expression increased about 2-fold, and collagen IX expression increased 4-fold compared with non- and control-transfected cells.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of varying MGP expression on marker gene expression in response to BMP-2. Upper panel, expression of differentiation markers in C3H10T1/2 cells transfected with hMGP or AS-hMGP after 21 days in culture; treatment with vehicle alone (-) or rhBMP-2 (500 ng/ml) (+), compared with nontransfected (NT) and control-transfected (CT) cells. Total RNA and cDNA was prepared, and PCR was performed using specific primers for osteocalcin (osteogenic differentiation), collagen IX (chondrogenic differentiation), and PPAR-gamma 2 (adipogenic differentiation). GAPDH is shown for comparison. Lower panel, relative signal intensity of the three markers after normalization to GAPDH. The results are expressed as fold increase of expression with respect to vehicle-treated control and are shown as the mean and S.D. of at least three independent determinations.

Adipogenic differentiation appeared to be only partially inhibited in cells expressing hMGP based on only partial inhibition of PPAR-gamma 2. This may be due to the base-line expression of BMP-4 which induces adipogenic differentiation in these cells (17).

To confirm the RT-PCR results, we performed immunoradiometric quantitation of mouse osteocalcin in cell media (Fig. 5, upper panel) and immunoblotting for PPAR-gamma protein and collagen IX (Fig. 5, lower panel). These results were consistent with the findings of the RT-PCR. The antibody for PPAR-gamma protein recognizes both PPAR-gamma 1, which is widely expressed in a variety of cells (16), and PPAR-gamma 2. PPAR-gamma 2 contains 28 extra amino acids at the N terminus (16) (~3.5 kDa) and thus corresponds to the upper band.



View larger version (40K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of varying expression on marker protein levels in response to BMP-2. Mouse osteocalcin in media as determined by immunoradiometric assay (top), collagen IX (middle), and PPAR-gamma protein (bottom) in cell extracts as shown by immunoblotting from C3H10T1/2 cells transfected with hMGP or AS-hMGP after 21 days in culture: treatment with vehicle alone (-) or rhBMP-2 (500 ng/ml) (+), compared with nontransfected (NT) and control-transfected (CT) cells. 30 µg of protein was loaded per lane for immunoblotting. Fold induction was determined by comparison of the signal intensity of treated cells to that of nontreated cells.

Nonquantitative histochemical stainings (Fig. 6) further confirmed an inhibition of osteogenic and chondrogenic differentiation in hMGP-overexpressing cells. As expected, Oil Red O staining showed occasional adipocytes (Fig. 6, left middle panel). Positive staining for all lineages was seen in nontransfected control cells and in AS-hMGP-overexpressing cells.



View larger version (135K):
[in this window]
[in a new window]
 
Fig. 6.   Histochemical staining of C3H10T1/2 cells transfected with hMGP and AS-hMGP after treatment with rhBMP-2 for 21 days. Nontransfected (NT) control cells are shown in the upper panels, hMGP cells in the middle panels, and AS-hMGP cells in the lower panels. Oil Red O staining (adipogenic differentiation) is shown in the left panels, von Kossa staining (osteogenic differentiation) in the middle panels, and Alcian Blue staining (chondrogenic differentiation) in the right panels. Original magnification × 40.

Thus, in cells overexpressing hMGP, BMP-2 activity was reduced, and in cells overexpressing AS-hMGP, BMP-2 activity was increased.

Effect of BMP-2 on MGP-deficient Mouse Cells-- To test our results ex vivo, mixed aortic cells from homozygous MGP-/- and heterozygous MGP+/- mice as well as wild-type controls were harvested and cultured. The cells were treated with rhBMP-2 at a concentration of 500 ng/ml for 14-16 days.

When MGP-/- cells were treated with BMP-2, chondrogenic differentiation was induced based on strong induction of alkaline phosphatase in colonies of rounded cells (Fig. 7A) and formation of distinct colonies of chondrocytes producing acidic mucopolysaccharides (18) (Fig. 7A). In MGP+/- or control +/+ cells, BMP-2 failed to induce chondrogenic differentiation based on histochemical staining, as well as RT-PCR and immunoblotting for collagen IX (data not shown). However, in MGP+/- cells, BMP-2 did induce osteogenic differentiation based on mineral formation and increased osteocalcin expression (Fig. 7, B and C). Although a low level of osteocalcin expression was found at base line in wild-type cells, this showed a decreasing trend with BMP-2. The differential effect may be the result of a changed ratio of MGP relative to BMP-2 resulting in relatively unopposed BMP activity.



View larger version (51K):
[in this window]
[in a new window]
 
Fig. 7.   A, histochemical staining for alkaline phosphatase (top) and cartilage acidic mucopolysaccharides (Alcian Blue) (bottom) demonstrating the effect of rhBMP-2 (500 ng/ml) for 14-16 days on mixed aortic cells isolated from homozygous MGP null mouse (MGP-/-). B, histochemical staining for mineral (Alizarin Red) demonstrating the effect of rhBMP-2 for 14-16 days on aortic cells isolated from wild-type mouse (MGP+/+) (left), and heterozygous MGP null mouse (MGP+/-) (right). Original magnification × 100. C, expression of osteocalcin in MGP+/+ and MGP+/- cells after treatment with vehicle alone (-) or rhBMP-2 (500 ng/ml) (+) for 14-16 days. Fold induction was determined by comparison of the signal intensity for treated cells to that of nontreated cells.

These results differ from those in C3H10T1/2 cells, in that osteogenic and chondrogenic differentiation in mouse cells appeared to be confined to heterozygous or homozygous cells, respectively. It is possible that the C3H10T1/2 cells are less differentiated than the isolated vascular cells, retaining a higher degree of pluripotentiality. Equally possible is that cell isolation procedures and/or culture conditions select for certain types of cells resulting in the observed differences.

Effect of MGP-FLG on BMP-induced Differentiation-- In the experiments described above, mRNA levels of MGP were modulated by overexpression of hMGP or AS-hMGP or by using cells from MGP-deficient mice. Even though mRNA levels most commonly reflect protein levels, this may not always be the case. To determine directly the effect of MGP protein on BMP-induced differentiation, we tagged the C-terminal end of hMGP for easy detection in conditioned media (Fig. 8A, inset), and we compared the response to BMP-2 of C3H10T1/2 cells expressing hMGP-FLAG with those expressing nontagged hMGP. No significant difference was detected, here demonstrated by comparing BMP-2-induced alkaline phosphatase activity, an early marker for osteoblastic and chondrocytic differentiation (Fig. 8A). These results indicate that MGP protein is secreted by the transfected cells and that the experimentally tagged protein retains the function of the original MGP.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 8.   A, alkaline phosphatase activity in C3H10T1/2 cells transfected with hMGP and hMGP-FLAG after 12 days in culture with treatment with vehicle alone or rhBMP-2 (500 ng/ml). Nontransfected (NT) and control-transfected (CT) cells are shown for comparison. Inset, Western blot demonstrating secreted hGMP-FLAG in conditioned media. B, alkaline phosphatase activity in nontransfected C3H10T1/2 cells after 12 days in culture with treatment with rhBMP-2 (estimated 500 ng/ml) alone or in combination with ~3-fold molar excess hMGP-FLAG. Control media and hMGP-FLAG alone are shown for comparison. Inset, Western blot demonstrating secreted rhBMP-2 in conditioned media.

Nontransfected C3H10T1/2 cells were then treated with conditioned media containing BMP-2 alone or in combination with ~3-fold molar excess hMGP-FLAG. Conditioned media containing BMP-2 (Fig. 8B, inset) or hGMP-FLAG was prepared from HEK293 cells transfected with expression vectors of BMP-2 or hMGP-FLAG. Conditioned media containing both proteins was obtained by cotransfecting the hMGP-FLAG and the BMP-2 vector at a 3:1 molar ratio or by combining conditioned media from singly transfected cells at a comparable ratio.

Alkaline phosphatase was determined using a 96-well assay after 12-14 days of incubation with conditioned media (Fig. 8B). The results show that exogenous addition of hMGP-FLAG to BMP-2-containing media inhibits BMP-2-induced differentiation as measured by alkaline phosphatase. No significant difference was seen in experiments using conditioned media from cotransfected HEK293 cells versus singly transfected cells. This result places the site of action for MGP extracellularly.

Taken together, the three sets of experiments described above suggest that MGP directs mesenchymal differentiation by modulating BMP activity.

Effects of MGP Domains on BMP-induced Differentiation-- To test whether fragments of MGP would retain the effect of full-length MGP on BMP-2-induced differentiation, we established stable cell lines overexpressing selected subdomains of hMGP by transfection of C3H10T1/2 cells. Three vectors were transfected, one with the mid-region (usually subjected to gamma -carboxylation) alone (mid-MGP, aa 35-54) and the other two with the mid-region combined with either the N terminus (N-MGP, aa 1-54) or the C terminus (C-MGP, aa 35-84) (Fig. 1). Unique RT-PCR products for each vector were detected from cells transfected with the respective vector using primers recognizing only human MGP (Fig. 9, upper panel). The relative expression by RT-PCR was determined by multiple cycles of RT-PCR using comparable primer pairs and adjustment to GAPDH expression and length of amplified sequence. Expression was compared with that of hMGP-expressing cells (Fig. 9, lower panel). The lowest expression was found in N-MGP cells, which is comparable to that of confluent AS-hMGP. Intermediate expression was found in hMGP and mid-MGP cells, and the highest expression is found in C-MGP cells.



View larger version (40K):
[in this window]
[in a new window]
 
Fig. 9.   Top panel, RT-PCR demonstrating specific expression of transfected constructs containing hMGP (sense or antisense orientation) and selected subdomains of hMGP in C3H10T1/2 cells after 14 days in culture. The sense PCR primer for human MGP (Table I) was used as the upstream primer for all constructs. As downstream primers, the antisense human MGP-primer was used for the hMGP, AS-hMGP, and the C-MGP constructs; the MGPX-3'-primer was used for the N-MGP and the mid-MGP construct. The size of the respective PCR product is shown to the left. Bottom panel, relative signal intensity of the different constructs after normalization to GAPDH and length of PCR product. The signal corresponding to hMGP expression was regarded as 1-fold.

The phenotype of cells expressing N-MGP or the mid-MGP resembled that of cells expressing AS-hMGP (Fig. 4) whereas that of cells expressing C-MGP did not. In N-MGP- and mid-MGP-expressing cells, there was a significant enhancement in osteogenic differentiation as assessed by RT-PCR of osteocalcin (Fig. 10). Even without added BMP-2, osteogenic differentiation occurred in these cells based on an approximate 4-fold increase in osteocalcin expression compared with non- and control-transfected cells (Fig. 10) and positive mineral production (von Kossa staining, data not shown). Addition of BMP-2 had little additional effect on osteocalcin expression in N-MGP cells but induced it about 2-fold in mid-MGP cells (Fig. 10), which may be attributable to the higher relative expression of this construct compared with N-MGP (Fig. 8) or to specific characteristics of this MGP domain. Chondrogenic differentiation was also enhanced about 2-fold in N-MGP cells and 4-fold in mid-MGP cells compared with non- or control-transfected cells as assessed by RT-PCR for collagen IX (Fig. 10). This finding suggests that the mid-MGP fragment is the most efficient in enhancing BMP-2 activity either due to its particular level of expression or domain characteristics.



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 10.   Upper panel, expression of cell-specific differentiation markers in cells transfected with selected domains of hMGP after 21 days of culture: treatment with vehicle alone (-) or rhBMP-2 (500 ng/ml) (+), compared with nontransfected (NT) and control-transfected (CT) cells. Total RNA and cDNA were prepared, and PCR was performed using specific primers for osteocalcin (osteogenic differentiation) and collagen IX (chondrogenic differentiation). GAPDH is shown for comparison. Lower panel, relative signal intensity of the two markers after normalization to GAPDH. The results are expressed as fold increase of expression in respective vehicle-treated control and are the means of at least three independent determinations.

In cells expressing C-MGP, no enhancement of osteocalcin was seen at base line, and the response to BMP-2 overall was not different from that of control cells (Fig. 10). Induction of adipogenic differentiation was similar in all cells, between 2.5- and 3.5-fold, without clear enhancement or inhibition (data not shown).

Thus, the intact MGP protein appears to be required to inhibit BMP-2 activity, whereas the N-MGP and mid-MGP subdomains have the opposite effect. One possible mechanism is through interference with MGP function.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A possible clue to the mechanism of the effect of MGP on differentiation comes from earlier reports that MGP is associated with BMP, during BMP purification from bone (5). To determine whether the observed association has a functional significance, and whether it serves as the mechanism for MGP's modulation of differentiation, we tested the effect of MGP on BMP activity. The findings presented in this paper suggest that MGP modulates BMP-2-induced differentiation.

In C3H10T1/2 cells, MGP overexpression suppresses the effects of BMP-2, whereas overexpression of antisense to MGP enhances these effects. It is not clear how AS-hMGP exerts its effect. The most straightforward explanation is that the 3-fold excess of AS-hMGP mRNA (Fig. 2) reacts with the endogenous MGP mRNA to decrease its translation. Our results show that even when present at only 3-fold excess in the media, hMGP-FLAG inhibits the response to BMP-2, which suggests that small changes in MGP expression and MGP levels may have significant impact. Alternatively, inhibitory peptides may be produced from the reversed hMGP sequence. Inspecting the sequence, translation of two potential peptides (22 and 6 amino acids respectively) is theoretically possible. However, extensive GenBankTM searches did not show any obvious similarity with known proteins, including MGP and BMP, which could explain the effect of AS-hMGP.

The importance of low density plating of C3H10T1/2 cells to be able to study the differentiation of individual cells or colonies and to avoid confusing results due to too high cell density has been emphasized by Wang et al. (7). Interestingly, there appears to be a lower cell density in cultures that failed to differentiate. Since the cells were plated carefully at identical densities, this difference would be attributed to BMP-2 treatment. Two possibilities are that BMP-2 directly affects cell density or that induction of differentiation by BMP-2 affects cell density. The latter is more likely, based on the results of Wang et al. (7) that induction of differentiation by BMP-2 causes a decrease in contact inhibition resulting in ultimately greater cell density. Thus, the apparent difference in cell density is an expected result, rather than a cause of the differentiation.

All markers of osteogenic differentiation increased in BMP-2-treated AS-hMGP cells except for one, osteocalcin levels measured in the media. This phenomenon of decreased secretion of soluble osteocalcin in BMP-2-stimulated cells undergoing osteogenic differentiation has been described previously (19) and may be attributed to adsorption of osteocalcin by hydroxyapatite mineral.

Although osteogenic and chondrogenic differentiation was affected, the effect of MGP on adipogenic differentiation was variable. Even though C3H10T1/2 cells express minimal amounts of BMP-2 at base line (20), they do express other BMP (20, 21) including significant amounts of BMP-4, a strong adipogenic inducer in these cells (17). Thus, other factors regulating adipogenesis may explain the variable effect on adipogenesis.

Ex vivo results showed that BMP-2 induced chondrogenic and osteogenic differentiation in MGP-/- and MGP+/- cells, respectively, which differs from the results in the C3H10T1/2 cells. In C3H10T1/2 cells, intermediate levels of BMP-2 have been reported to favor formation of osteoblastic cells, and high levels to favor chondrocytes (7), but not to the exclusion of differentiation along other lineages. It is possible that the procedures used to obtain cells from the respective aortas may select for cells with more limited inducibility compared with C3H10T1/2 cells. Culture conditions and time in culture may be other factors affecting the observed differentiation.

MGP appears to be an important factor in ensuring correct differentiation of vascular smooth muscle cells based on the profound changes seen in MGP-deficient mice where the whole media are replaced by chondrocyte-like cells undergoing endochondral ossification (4). Interestingly, BMP-2 is expressed in the embryonic aorta (embryonic day 10.5) when the aorta is still a tube lined with a single layer of cells (22), coinciding with the time of initial media formation (23). In vitro experiments have shown that BMP-2 is able to induce smooth muscle cell differentiation in neural crest-derived stem cells (22). We speculate that the absence of MGP may allow for uncontrolled BMP-2 activity at a stage when smooth muscle cell precursors are easily triggered to undergo endochondral bone formation leading to the phenotype seen in MGP-deficient mice.

By FLAG-tagging hMGP and using HEK293 cells for producing MGP, we facilitated both the detection of the protein in medium and avoided handling of purified hMGP which is poorly soluble in water-based buffers (1). Functionally, hMGP-FLAG retained the function of untagged hMGP when expressed in C3H10T1/2 cells. The same effect was seen when hMGP-FLAG was added to the culture medium that localizes the action of MGP to the extracellular space. A possible in vivo scenario is that MGP binds BMP-2, preventing its interaction with cell surface receptors and retaining BMP during integration with bone matrix. This mechanism would account for the earlier observation of BMP being tightly associated with MGP during purification of bone proteins (5).

The effect of full-length MGP did not seem to be retained by any of the three selected subdomains. Instead, two of the three subdomains had the reverse effect of full-length MGP, may be due to different expression levels or domain characteristics. MGP is mainly attached to the organic matrix if bone (24). Thus, possible mechanisms for the MGP fragments would be to interfere with the matrix attachment of MGP or its interaction with BMP, in that way enhancing BMP activity. Alternatively, the MGP domains may activate other or additional osteoinductive factors such as GDF-7 (21), possibly explaining the base-line differentiation observed without BMP-2 treatment in N-MGP- and mid-MGP-expressing cells.

Further support for the role of MGP in cell differentiation is that MGP expression is strictly limited to specific stages and zones of chondrocyte development (2) and that the MGP null mouse has disorganized epiphyseal growth plates (4). In addition, Yagami et al. (3) showed that overexpression of MGP in developing limb buds delayed chondrocyte maturation and blocked endochondral ossification.

There are precedents for modulation of BMP activity. Embryonic regulators including chordin (25), noggin (26), gremlin, cerberus, and DAN (27) directly bind and inhibit BMP despite their widely different primary structures. In the case of transforming growth factor-beta , a member of the same superfamily of growth factors as BMP, the matrix protein betaglycan sequesters transforming growth factor-beta and limits access to signaling receptors (28, 29).

Together, our findings suggest MGP modulates mesenchymal cell differentiation and that the mechanism is, at least in part, modulation of the potent bone differentiation factor, BMP-2.


    ACKNOWLEDGEMENTS

We are grateful to Shi-Chi Kao for technical assistance, Dr. Gerard Karsenty at Baylor College of Medicine for MGP-deficient mice breeder pair, and Genetics Institute for recombinant human BMP-2.


    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants 30568 and 04270, the Howard Hughes Medical Institute, the Laubisch Fund, and the Atorvastatin Research Award Program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Fellow of the American Heart Association, Greater Los Angeles Affiliate, during part of this research project. To whom correspondence and reprint requests should be addressed: Division of Cardiology, UCLA School of Medicine, Box 951679, Rm. 47-123 CHS, Los Angeles, CA 90095-1679. Tel.: 310-206-2677; Fax: 310-825-4963, E-mail: kbostrom@mednet.ucla.edu.

Published, JBC Papers in Press, January 26, 2001, DOI 10.1074/jbc.M008103200


    ABBREVIATIONS

The abbreviations used are: MGP, matrix GLA protein; GLA, carboxyglutamic acid; BMP, bone morphogenetic proteins; rh, recombinant human; h, human; AS, antisense; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-PCR; aa, amino acids; FBS, fetal bovine serum; Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; MES, 4-morpholineethanesulfonic acid; PPAR-gamma , peroxisome proliferator-activated receptor gamma ; MOPS, 4-morpholinepropanesulfonic acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; AP, alkaline phosphatase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Price, P. A., and Williamson, M. K. (1985) J. Biol. Chem. 260, 14971-14975[Abstract/Free Full Text]
2. Luo, G., D'Souza, R., Hogue, D., and Karsenty, G. (1995) J. Bone Miner. Res. 10, 325-334[Medline] [Order article via Infotrieve]
3. Yagami, K., Suh, J.-O., Enomoto-Iwamoto, M., Koyama, E., Abrams, W. R., Shapiro, I. M., Pacifici, M., and Iwamoto, M. (1999) J. Cell Biol. 147, 1097-1108[Abstract/Free Full Text]
4. Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., and Karsenty, G. (1997) Nature 386, 78-81[CrossRef][Medline] [Order article via Infotrieve]
5. Urist, M. R., Huo, Y. K., Brownell, A. G., Hohl, W. M., Buyske, J., Lietze, A., Tempst, P., Hunkapiller, M., and DeLange, R. J. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 371-375[Abstract]
6. Hirschi, K. K., Rohovsky, S. A., and D'Amore, P. A. (1998) J. Cell Biol. 141, 805-814[Abstract/Free Full Text]
7. Wang, E. A., Israel, D. I., Kelly, S., and Luxenberg, D. P. (1993) Growth Factors 9, 57-71[Medline] [Order article via Infotrieve]
8. Bächner, D., Ahrens, M., Schröder, D., Hoffman, A., Lauber, J., Betat, N., Steinert, P., Flohé, L., and Gross, G. (1998) Dev. Dyn. 213, 398-411[CrossRef][Medline] [Order article via Infotrieve]
9. Kiefer, M. C., Bauer, D. M., Young, D., Hermsen, K. M., Masiarz, F. R., and Barr, P. J. (1988) Nucleic Acids Res. 16, 5213[Medline] [Order article via Infotrieve]
10. Freshney, R. I. (1987) in Culture of Animal Cells: A Manual of Basic Techniques, 2nd Ed., pp. 115-118; 272-273, Wiley-Liss, Inc., New York
11. Balica, M., Boström, K., Shin, V., Tillisch, K., and Demer, L. L. (1997) Circulation 95, 1954-1960[Abstract/Free Full Text]
12. Warman, M., Kimura, T., Muragaki, Y., Castagnola, P., Tamei, H., Iwata, K., and Olsen, B. R. (1993) Matrix 13, 149-156[Medline] [Order article via Infotrieve]
13. Cancela, M. L., Hu, B., and Price, P. A. (1997) J. Cell. Physiol. 171, 125-134[CrossRef][Medline] [Order article via Infotrieve]
14. Celeste, A. J., Rosen, V., Buecker, J. L., Kriz, R., Wang, E. A., and Wozney, J. M. (1986) EMBO J. 5, 1885-1890[Abstract]
15. Kolettas, E., Buluwela, L., Bayliss, M. T., and Muir, H. I. (1995) J. Cell Sci. 108, 1991-1999[Abstract/Free Full Text]
16. Cowherd, R. M., Lyle, R. E., and McGehee, R. E., Jr. (1999) Cell. Dev. Biol. 10, 3-10[CrossRef]
17. Butterwith, S. C., Wilkie, R. S., and Clinton, M. (1996) Biochem. Soc. Trans. 24, 163[Medline] [Order article via Infotrieve]
18. Asahina, I., Sampath, T. K., Nishimura, I., and Hauschka, P. V. (1993) J. Cell Biol. 123, 921-933[Abstract]
19. Gori, F., Thomas, T., Hicok, K. C., Spelsberg, T. C., and Riggs, B. L. (1999) J. Bone Miner. Res. 14, 1522-1535[Medline] [Order article via Infotrieve]
20. Gazit, D., Ebner, R., Kahn, A. J., and Derynck, R. (1993) Mol. Endocrinol. 7, 189-198[Abstract]
21. Kaps, C., Lauber, J., Ju, W., Czichos, S., and Gross, G. (1998) Biochem. Soc. Trans. 26, 27-32[Medline] [Order article via Infotrieve]
22. Shah, N. M., Groves, A. K., and Anderson, D. J. (1996) Cell 85, 331-343[Medline] [Order article via Infotrieve]
23. Hungerford, J. E., and Little, C. D. (1999) J. Vasc. Res. 36, 2-27[CrossRef][Medline] [Order article via Infotrieve]
24. Hale, J. E., Fraser, J. D., and Price, P. A. (1988) J. Biol. Chem. 263, 5820-5824[Abstract/Free Full Text]
25. Piccolo, S., Sasai, Y., Lu, B., and De Robertis, E. M. (1996) Cell 86, 589-598[Medline] [Order article via Infotrieve]
26. Brunet, L. J., McMahon, J. A., McMahon, A. P., and Harland, R. M. (1998) Science 280, 1455-1457[Abstract/Free Full Text]
27. Hsu, D. R., Economides, A. N., Wang, X., Eimon, P. M., and Harland, R. M. (1998) Mol. Cell 1, 673-683[Medline] [Order article via Infotrieve]
28. Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J. L., Lane, W. S., and Massagué, J. (1991) Cell 67, 785-795[Medline] [Order article via Infotrieve]
29. Wang, X.-F., Lin, H., Ng-Eaton, E., Downward, J., Lodish, H. F., and Weinberg, R. A. (1991) Cell 67, 797-805[Medline] [Order article via Infotrieve]
30. Chen, L., O'Bryan, J. P., Smith, H. S., and Liu, E. (1990) Oncogene 5, 1391-1395[Medline] [Order article via Infotrieve]
31. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., Hewick, R. M., and Wang, E. A. (1988) Science 242, 1528-1534[Medline] [Order article via Infotrieve]
32. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. (1994) Genes Dev. 8, 1224-1234[Abstract]
33. Abe, N., Yoshioka, H., Inoue, H., and Ninomoya, Y. (1994) Biochim. Biophys. Acta 1204, 61-67[Medline] [Order article via Infotrieve]
34. Tokunaga, K., Nakamura, Y., Sakata, K., Fujimori, K., Ohkubo, M., Sawada, K., and Sakiyama, S. (1987) Cancer Res. 47, 5616-5619[Abstract]
35. Ikeda, T., Yamaguchi, A., Icho, T., Tsuchida, N., and Yoshiki, S. (1991) J. Bone Miner. Res. 6, 1013-1017[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.